Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
Condition(s):Sintilimab; Lung Cancer; Anlotinib; ChemotherapyLast Updated:January 2, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Sintilimab; Lung Cancer; Anlotinib; ChemotherapyLast Updated:January 2, 2024Active, not recruiting
Condition(s):Rectal Cancer; Pathological Complete Response; Disease Free SurvivalLast Updated:March 22, 2023Recruiting
Condition(s):Breast Cancer; Metabolic SyndromeLast Updated:February 15, 2024Recruiting
Condition(s):Breast CancerLast Updated:July 5, 2019Completed
Condition(s):Locally Advanced Rectal CancerLast Updated:September 15, 2023Recruiting
Condition(s):Squamous Cell Carcinoma; Esophageal Cancer; Perioperative PeriodLast Updated:December 12, 2019Unknown status
Condition(s):Prostate CancerLast Updated:April 28, 2015Completed
Condition(s):Non Small Cell Lung CancerLast Updated:March 15, 2024Not yet recruiting
Condition(s):SBRTLast Updated:March 12, 2024Recruiting
Condition(s):Neoplasms, BreastLast Updated:September 21, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.